Peizhi Li

Dr. Peizhi Li

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PLPeizhi Li
Peizhi Li
GAGuohua An
Guohua An
Recreational cannabis use has increased notably in the United States in the past decade, with a recent surge in oral consumption. This trend has raised concerns about driving under the influence. Current cannabis‐impaired driving laws lack standardization, with some states implementing blood Δ9‐tetrahydrocannabinol (THC) per se limits (1, 2, and 5 ng/mL). However, these limits have been criticized for their inaccuracy and unreliability, highlighting the need for legal refinement. Addressing this issue requires understanding the complex pharmacokinetics (PK) and pharmacodynamics (PD) of THC, cannabis's primary psychoactive component, which can be characterized using a population PK model. However, existing PK models mainly focus on inhalation data and do not account for the growing number of oral cannabis users. To bridge this gap, a semi‐mechanistic population PK model was developed using data from 10 published studies following intravenous or oral administration of cannabis to characterize THC and its metabolites in oral users. Simulated THC plasma concentrations for doses from 2.5 mg to 100 mg in frequent and occasional users were used to evaluate the effectiveness of existing per se limits. Results showed that the 1 ng/mL limit was least effective due to a high risk of false positives, while the 2 and 5 ng/mL limits remain inconclusive due to limited PD data linking blood THC levels to impairment. These findings suggest that the existing per se laws may not fully address the complexity of cannabis impairment, underscoring the need for further research and refinement of cannabis‐impaired driving laws.

6 January 2026 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
MXMin Xu
Min Xu
XYXuanzhen Yuan
Xuanzhen Yuan
PLPeizhi Li
Peizhi Li
TBThanh Bach
Thanh Bach
HZHao-Jie Zhu
Hao-Jie Zhu
GAGuohua An
Guohua An
The phenomenon of nonlinear pharmacokinetics (PK) mediated by a drug’s pharmacological target, also known as target-mediated drug disposition (TMDD), has been increasingly observed in small molecules in the past decade. TMDD class effect with remarkably similar nonlinear PK behaviors has been reported in 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors, monoamine oxidase type B (MAO-B) inhibitors, and soluble epoxide hydrolase (sEH) inhibitors. We anticipated that the occurrence of TMDD class effect might be due to their target capacities falling within a specific range, where nonlinear PK mediated by target binding are more likely to be evident. To test our hypothesis, we employed a mass spectrometry (MS)-based global proteomics approach to quantify the absolute protein concentrations of 11β-HSD1, sEH, and MAO-B in different tissues across species. The estimated total amounts of 11β-HSD1, MAO-B, and sEH in humans were approximately 4994, 4629, and 4137 nmol, respectively. The comparable abundance levels of these proteins suggest that TMDD is more likely to be observed when a drug binds to a target within a specific range, potentially between 1000 nmol and 10000 nmol, which corresponds to nonlinear PK at doses of 1–10 mg for a compound with a molecular weight of 400 g/mol. Our study highlights the importance of early target quantification and provides valuable insights into predicting unusual nonlinear PK caused by TMDD. Additionally, this proteomics-based approach for quantifying absolute target capacity could serve as a valuable tool for both industry and academic researchers in investigating other pharmacological targets. Graphical Abstract

15 May 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PLPeizhi Li
Peizhi Li
GAGuohua An
Guohua An
The rising cases of cannabis‐impaired driving present a looming public safety concern that's currently addressed through varying state regulations. However, these regulations are yet validated and lack scientific robustness. One of the roadblocking factors is our insufficient understanding of THC's pharmacokinetics (PK) and pharmacodynamics (PD) due to limited clinical data. Therefore, we call for joint efforts among researchers and policymakers to conduct more comprehensive cannabis PK/PD studies to improve and validate existing cannabis driving regulations.